GABARAP sequesters the FLCN-FNIP tumor suppressor complex to couple autophagy with lysosomal biogenesis.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
Oct 2021
Historique:
entrez: 1 10 2021
pubmed: 2 10 2021
medline: 2 10 2021
Statut: ppublish

Résumé

Adaptive changes in lysosomal capacity are driven by the transcription factors TFEB and TFE3 in response to increased autophagic flux and endolysosomal stress, yet the molecular details of their activation are unclear. LC3 and GABARAP members of the ATG8 protein family are required for selective autophagy and sensing perturbation within the endolysosomal system. Here, we show that during the conjugation of ATG8 to single membranes (CASM), Parkin-dependent mitophagy, and

Identifiants

pubmed: 34597140
doi: 10.1126/sciadv.abj2485
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eabj2485

Auteurs

Jonathan M Goodwin (JM)

Casma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.

Ward G Walkup (WG)

Casma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.

Kirsty Hooper (K)

Signalling Programme, Babraham Institute, Cambridge, UK.

Taoyingnan Li (T)

Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada.
Cell Biology Program, Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.

Chieko Kishi-Itakura (C)

Imaging Facility, Babraham Institute, Cambridge, UK.

Aylwin Ng (A)

Casma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.

Timothy Lehmberg (T)

Casma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.

Archana Jha (A)

Casma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.

Sravya Kommineni (S)

Casma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.

Katherine Fletcher (K)

Signalling Programme, Babraham Institute, Cambridge, UK.

Jorge Garcia-Fortanet (J)

Casma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.

Yaya Fan (Y)

Viva Biotech, Shanghai, China.

Qing Tang (Q)

Viva Biotech, Shanghai, China.

Menghao Wei (M)

Viva Biotech, Shanghai, China.

Asmita Agrawal (A)

Sai Life Sciences Limited, Pune 411057, Maharashtra, India.

Sagar R Budhe (SR)

Sai Life Sciences Limited, Pune 411057, Maharashtra, India.

Sreekanth R Rouduri (SR)

Sai Life Sciences Limited, Pune 411057, Maharashtra, India.

Dan Baird (D)

Casma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.

Jeff Saunders (J)

Casma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.

Janna Kiselar (J)

NEO Proteomics Inc., Cleveland, OH 44106, USA.

Mark R Chance (MR)

NEO Proteomics Inc., Cleveland, OH 44106, USA.
School of Medicine, Case Western Reserve University, Cleveland, OH 44016, USA.

Andrea Ballabio (A)

Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Medical Genetics Unit, Department of Medical and Translational Science, Federico II University, Naples, Italy.
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX 77030, USA.
SSM School for Advanced Studies, Federico II University, Naples, Italy.

Brent A Appleton (BA)

Casma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.

John H Brumell (JH)

Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada.
Cell Biology Program, Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
Institute of Medical Science, University of Toronto, Toronto, ON M5S 1A8, Canada.
SickKids IBD Centre, Hospital for Sick Children, Toronto, ON M5G 0A4, Canada.

Oliver Florey (O)

Signalling Programme, Babraham Institute, Cambridge, UK.

Leon O Murphy (LO)

Casma Therapeutics, 400 Technology Sq, Cambridge, MA 02139, USA.

Classifications MeSH